Engage Bio
Developing Tethosomes, a new class of non-viral DNA medicines to address both hurdles that have held back the field of non-viral DNA: potency and toxicity.
Engage Bio’s approach can induce high levels of tissue or tumor specific protein expression, for months and potentially years. With applications ranging from long-acting gene replacement to cancer immunotherapy, the team at Engage Bio is now charting the path toward their first human clinical programs.